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are already underway at the NIEHS, as part
ofthe EMF RAPID (Electric and Magnetic
Fields Research and Public Information
Dissemination) Program. In fact, Program
Director Gary Boorman reports, NIEHS
researchers recently attempted to replicate
the German study ofbreast cancer develop-
ment in rodents. Boorman expects to see
completed data from that study within 8
months. A second, two-year study involving
100 animals subjected to slightly lower
chemical doses in conjunction with longer-
term exposure to EMFs should also be com-
pleted soon, he says. "The NAS report was a
good report," he says. "But it did not
include many ofthe RAPIDstudies, because
they didn't look at much data after 1994.
We hope to prepare a report for Congress in
1998 that will allow us to examine the
wealth ofdataproduced since 1994."
The congressionally mandated NAS
report-prepared by a 16-member commit-
tee including David A. Savitz, a professor at
the University ofNorth Carolina at Chapel
Hill whose carefully controlled epidemiolog-
ical studies have consistently suggested an
association between EMFs and cancer-may
deal another blow to a draft report of the
National Council on Radiation Protection
and Measurements (NCRP), which calls for
a 2-milligauss limit on EMFs near day-care
centers, schools, playgrounds, and newly
built homes within the next 10 years.
Portions of the draft appeared in the
July/August 1995 issue ofMicrowave News,
though it still has not cleared the NCRP's
exhaustive peer-review process. "It seems to
have entered an NCRP black hole,"
observed MNEditor Louis Slesin, who faults
the NAS report foremphasizing the need for
"conclusive" evidence of an EMF-related
health hazard. "That's a very harsh burden,"
he said, adding that researchers have not
conclusively ruled out EMFs as the cause of
reported increases in childhood leukemia.
Until such questions are resolved, says
Jack Sahl, a senior research scientist and
manager of the Health Research and
Evaluation Division at Edison International
in Rosemead, California, utilities and policy-
makers would be wise to adopt "precaution-
based" strategies for minimizing anypossible
health risks. [See EHP 104:908-911 (1996).]
For example, Sahl said in an interview,
Edison International has prepared a manual
offering common-sense guidelines for mini-
mizing EMF exposure risks when designing
new buildings. Similarly, since 1989, the
California Department of Education has
avoided building new schools in dose prox-
imityto high-voltage powerlines.
No federal legislation is pending to limit
EMF exposure, Sahi says, and policymakers
who once championed exposure limits,
including Representative George Miller (D-
California.), now seem to be backing away
from the issue. The $600,000 NAS report
was requested by Representative Joseph M.
McDade (R-Pennsylvania) in response to
constituent concerns in Scranton,
Pennsylvania, where a utility company
wanted to install high-voltage power lines
near homes. (McDade's press secretary, Jake
O'Donnell, says the power company subse-
quently decided to relocate its power lines.)
Though he hasn't identified a specific EMF
research agenda, O'Donnell says, McDade
will probably heed recommendations set
forth by the NAS committee, which recom-
mended more stringent epidemiological
studies incorporating accurate measure-
ments of magnetic fields inside homes and
strategies for answering questions about
childhood leukemia. The NAS report also
recommended a host of biological studies.
For example, the committee said,
researchers should identify the mechanism
by which EMFs seem to promote bone-
healing in animals.
New Protein Kinase Inhibitors
Swiss researchers are exploring a vast new sea
ofcompounds that attack cancer cells at the
genetic level. "Phenylamino-pyrimidines are a
new class of potent and selective protein
kinase inhibitors," saidJeurgZimmermann, a
project leader with the pharmaceutical divi-
sion ofCIBA-Geigy in Basel. The key to use
of the phenylamino-pyrimidines (PAPs),
Zimmermann said, is their selectivity. "A lot
ofcompounds can attack protein kinases," he
said, but if the compound doesn't select for
specific enzymes, the subject cannot survive.
PAPs tend to select certain protein kinases,
such as protein kinase C (PKC), a calcium-
dependent enzyme that is overexpressed in
tumor cells. Throttling PKC with PAPs may
result in the tumor being unable to grow or
reproduce, and can possibly make it regress.
Zimmermann said another kinase that is
commonly overexpressed in cases of
gliomablastoma, a usually fatal brain cancer,
is platelet-derived growth factor receptor
(PDGF-R). In some laboratory mice that
have been implanted with gliomablastoma
tumors, the introduction ofcertain PAPs has
brought the growth ofthe tumor to a stand-
still, has prevented other cells from develop-
ing the tumor, or has actually caused the
tumor to regress, said Zimmermann.
Zimmermann and his colleagues chose to
study the means of attacking the protein
kinases, ofwhich there are more than 200,
because ofthe molecules' roles in signal trans-
duction and cell proliferation, both ofwhich
are responsible for a cascade ofevents leading
to cancer growth and metastasis in the body.
In a presentation at the American
Chemical Society meeting in Orlando,
Florida, Zimmermann demonstrated how
rational drug design procedures, using pyrim-
idines-one of the main building blocks of
DNA and RNA-have resulted in the syn-
thesis of more than 500 compounds. Using
pyrimidines as a base, scientists add various
analogs to the pyrimidine until they discover
a compound that looks as if it will attack a
specific area ofa cancer cell. Typically, scien-
tists will develop numerous chemical vari-
eties. Although "only about 10% ofthe com-
pounds have shown any anticancer activity,"
Zimmermann said, several ofthe compounds
that did limit tumor growth are now being
studied further before they are tested in
humans. "We have to test toxicity and phar-
macokinetics to see if the drug gets into the
bloodstream and can be ofuse therapeutical-
ly," hesaid.
"Rational drug design," said Theodore
Friedmann, director ofthe gene therapy pro-
gram at the University of California at San
Diego, "is a common device utilized to man-
ufacture chemicals that are likely to have an
effect on treatment of some disease. Most
drugs are developed using this procedure in
laboratories, although other drugs are still
commonly found by investigating organic
compounds such as tropical earths."
By and large, Friedmann said, the use of
rational drug design will result in an incre-
mental increase in fighting a disease such as
cancer. "We have hundreds of compounds
that show some ability to fight cancer cells,"
he said, "which really testifies to the fact that
we have very few drugs that really work well
in destroying cancer cells. We use one for a
while and when that stops working we go to
another." But, he said, "occasionally some-
thing comes along that breaks the curve."
Zimmermann said he is encouraged that
some of the PAPs being scrutinized by his
team have shown a wide range ofsuccess on
various tumors, including brain, breast, and
bladder cell lines. More exciting, he said, is
that some ofthe compounds are so selective
they will inhibit PDGF-R, necessary for the
growth ofbrain cancer cells, but will have no
effect on other tumor lines, indicating an
ability to be carefully fine-tuned into specific
tumorkillers.
Fungi Fighting Back
Just as many bacteria and viruses have
become resistant to pharmaceuticals, fungi
have been developing drug resistance over the
past five years. At the same time, new fungal
pathogens are emerging and previously iden-
tified rare fungal pathogens are re-emerging,
resulting in rising morbidity, mortality, and
costs, according to a report byDennis Dixon,
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